Faulty Reagent Caused 'Marginal' Over-Reporting of Breast Cancer Recurrence With MammaPrint

An Agendia official said that the company has provided "new, corrected MammaPrint reports" for all of the physicians who received faulty results and has also implemented internal quality-control measures to guard against a similar issue in the future.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.